Joslin News & More
Joslin in the News
New allies in war on weight
Dr. Osama Hamdy, medical director of the Joslin Diabetes Center’s Obesity Clinical Program, says the idea of a weight loss pill like Gelesis100 is appealing, but he’s not yet convinced on its safety of effectiveness.“It looks like an interesting concept,” Hamdy said. But, “we need to wait for a bigger trial.” Gelesis intends to start a larger research trial soon in the United States and abroad.
Inhaled Insulin Afrezza: FAQ
George King, M.D., Chief Scientific Officer at Joslin, provides feedback on Afrezza, a rapid-acting insulin than can be inhaled and provides an alternative to taking insulin injections.
How aggressively should doctors treat type 2 diabetes?
Dr. David Erani, director of medical programs at Joslin Diabetes Center, said he’s seen diabetes patients who experience horrible symptoms from hypoglycemia when their A1C levels go below 8 percent and emphasized that doctors need to treat patients as individuals considering their age, personal preferences, and how they respond to a new medication when it comes to selecting a drug they’ll likely be on for the rest of their lives.
Blood from Young Mice Shown to Reverse Aging
“These are the tissues that are really affected by advancing age. Changes in these tissues are responsible for the changes that people worry about the most — loss of cognition and loss of independent function,” said Amy Wagers, Investigator in the Section on Developmental and Stem Cell Biology at Joslin and a professor of stem cell and regenerative biology at Harvard University.
Diabetes Ages the Brain by Two Years, Says Study
Gail Musen, Assistant Investigator in the Section on Clinical, Behavioral, and Outcomes Research at the Joslin, is investigating whether changes in the way the brain processes insulin may make it easier for the protein amyloid to accumulate and form the plaques that are responsible for Alzheimer’s.
Joslin CEO Focused on Innovation to Treat Diabetes after his own Son's Diagnosis
Boston Business Journal
John Brooks III, President and CEO of Joslin Diabetes Center, says there’s been a lot of healthcare innovation in the past decade in the analytics software space. The advent of smartphones has resulted in apps for diabetes that remind users when to take drugs or test blood sugar levels. Joslin began an Office of Commercialization and Ventures almost three years ago to help startup companies in diabetes. That ease in starting healthcare companies has led to more parents who, like him, have started their own businesses to make a product to treat diseases their children.
Diabetes Doubles Over Two Decades
"My hope, and obviously everybody's hope, is that 11% [of adults with diabetes] will go down further as there's improved access to healthcare for all Americans," said Martin J. Abrahamson, M.D., FACP, Senior Vice President of Medical Affairs at Joslin and Associate Professor of Medicine at Harvard Medical School.
Calling Obesity A Disease May Make It Easier to Get Help
Dr. Osama Hamdy, Medical Director of the Obesity Clinical Program at Joslin Diabetes Center, explains why the change by the American Medical Association is appropriate and why it will result in bettter care.
Exercise Can Turn 'Bad' Fat Into 'Good' Brown Fat
"Our results showed that exercise doesn't just have beneficial effects on muscle, it also affects fat," one of the researchers, Kristin Stanford, Ph.D., who is a postdoctoral fellow at Joslin Diabetes Center, said in a statement. "It's clear that when fat gets trained, it becomes browner and more metabolically active. We think there are factors being released into the bloodstream from the healthier fat that are working on other tissues."
How to Manage Type 1 Diabetes As You Age
US News and World Report
Saalfeld and Wallace are among 850 patients with Type 1 diabetes taking part in a study being conducted by Joslin Diabetes Center, an educational, research and clinical care organization affiliated with Harvard Medical School. The participants were selected from 3,900 Joslin medalists who have lived with Type 1 diabetes for various milestones, from 25 to 85 years.
Joslin Diabetes Center CEO Runs Health Care Nonprofit Like a Life Sciences Startup
“We’re a 115 year-old startup,” says Joslin Diabetes Center CEO John Brooks, who moved from board chairman to full-time CEO of the innovative health care organization in early 2011.
The Methodical Adventurer | Stem cell researcher Amy Wagers enjoys the thrill of discovery
In an HMS podcast, Amy Wagers, professor of stem cell and regenerative biology at Harvard and Joslin Diabetes Center, talks about why she is motivated by both the prospect of treating disease and the thrill of discovery.
When Fat Is Good: Brown Adipose Tissue (BAT) Shows Potential As Obesity Buster
Wall Street Journal
Dr. Aaron Cypess, of the Joslin Diabetes Center (JDC) and Beth Israel Deaconess Medical Center (BIDMC), has been studying the structural and functional differences between brown adipose tissue (BAT) and white adipose tissue for several years and asserts that brown fat tissue holds promise as an obesity treatment if researchers are able to harness the substance's ability to burn the extra stored lipids (fats) in white fat cells.
Diabetes Advice for the Elderly: Relax
New York Times
My mother has Type 2 diabetes, but she won’t eat. My father gets up and snacks in the middle of the night. My mom’s A1c is almost 8 percent. Why won’t she use her glucometer? Dr. Medha Munshi, director of the geriatrics program at the Joslin Diabetes Center in Boston, hears these and other gripes from her patients’ children all the time. And they’re right to worry about diabetes, which affects nearly 27 percent of older adults.
Director of Marketing and Communications
Phone: (617) 309-1957
Fax: (617) 309-2692
Please email media requests.